SMi's 4th Annual Ophthalmic Drugs Conference - Chairman's Invitation Released

SMi Group reports: Chairman of the 4th Annual Ophthalmic Drugs conference has invited experts in the industry to join.
By: SMi Group
 
LONDON - Oct. 15, 2021 - PRLog -- As Chair of the 4th Annual Ophthalmic Drugs conference (http://www.smi-online.co.uk/goto/www.ophthalmicdrugs.com.asp?emref=P-335ER1&amp), I cordially invite you to attend this anticipated event taking place on the 22nd and 23rd of November 2021 in London, UK, including a new post conference workshop day – featuring an interactive half-day workshop, on the 24th November 2021 in London, UK.

With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals. The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy.

The Ophthalmic Drugs conference will bring together expertise from individuals in multiple disciplines of the field. The packed two-day agenda will offer a series of presentations, through which you will gain insight into new industry developments and clinical trials, innovations in the treatment of rare diseases, regulatory perspectives, and advances in gene therapy. Furthermore, the workshop day will explore the growing industry focus on the development of novel methods of ocular drug delivery, giving an unmissable insight into this emerging field of drug development.

Attendees stand to gain many valuable insights from this event, such as:
  • Enhanced understanding of the newest techniques in ocular drug design and delivery
  • Exploration of the impacts and applications of controlled release technologies
  • Learning how advanced medical devices are changing the face of combined therapy
  • Exposure to the latest developments in overcoming the challenges of treating such a complex organ

Big Pharma & Biotech Speakers:
  • Aniz Girach, Chief Medical Officer, ProQR Therapeutics
  • Victor Chong, Global Medical Head, Retinal Health, Boehringer Ingelheim
  • Daniel Chung, Chief Medical Officer, SparingVision
  • Jaya Chidambaram, Associate Clinical Director, Roche Genentech
  • Kerrie Brady, Chief Executive Officer, Ocuterra Therapeutics
  • Peter Morgan-Warren, Ophthalmology Specialist; Senior Medical Advisor, Bayer
  • Gregoire Schwach, Leader Ocular and Drug Delivery, PTD Biologics Europe, Roche
  • Francine Behar-Cohen, Chief Innovation Officer, Eyevensys
  • Petra Kozma, Head of Clinical Development, Oxurion NV
  • Magali Taiel, Chief Medical Officer, Gensight-Biologics
  • Alan Franklin, CEO, ForwardVue Pharma
  • Brian Levy, CEO, InflammX Therapeutics

To find out more and view the full agenda for the day please visit www.ophthalmicdrugs.com/PR5PRLOG

Mitchell de Long
Vice President, Chemistry
Aerie Pharmaceuticals

(Conference Chairman for Ophthalmic Drugs)

Proudly Sponsored by Experimentica & TALLC

Contact
Richard Jones
***@smi-online.co.uk
End
Email:***@smi-online.co.uk Email Verified
Tags:Ophthalmics Drugs
Industry:Medical
Location:London City - London, Greater - England
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share